BioCentury | Aug 15, 2011
Company News

Tobira management update

...Manalapan, N.J. Business: Infectious Hired: Helen Jenkins as SVP of program leadership, formerly COO at Nuon Therapeutics Inc. WIR...
BioCentury | Jul 25, 2011
Company News

Portola management update

...Cardiovascular, Autoimmune, Cancer Hired: Michael Kitt as SVP and CMO, formerly EVP and CMO of Nuon Therapeutics Inc. WIR...
BioCentury | Jul 19, 2010
Clinical News

Tranilast: Phase I data

...total daily doses of 300, 600 or 900 mg tranilast between once- or twice-daily regimens. Nuon...
...keloid and hypertrophic scars and allergic conjunctivitis. Kissei was granted an exclusive option to license Nuon's...
...tranilast program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jul 19, 2010
Clinical News

Tranilast: Phase I data

...asthma, keloid and hypertrophic scars and allergic conjunctivitis. Kissei has an exclusive option to license Nuon's...
...tranilast program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jun 21, 2010
Clinical News

NU1618: Phase IIa data

...Patients received low- or high-dose NU1618, 300 mg/day tranilast, or 300 or 400 mg/day allopurinol. Nuon...
...in Japan and South Korea for bronchial asthma, keloid and hypertrophic scars and allergic conjunctivitis. Nuon's...
...the program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | May 17, 2010
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Metabolic Hired: Lee Rauch as president and CEO, formerly acting head of corporate development of Onyx Pharmaceuticals Inc. WIR Staff...
BioCentury | May 13, 2010
Company News

Nuon names Rauch CEO

...Autoimmune and metabolic company Nuon Therapeutics Inc. (San Mateo, Calif.) hired Lee Rauch as president and CEO. She...
BioCentury | Apr 26, 2010
Clinical News

NU1618: Phase IIb start

...This month, Nuon will begin a double-blind, active-controlled Phase IIb trial in 60 patients to compare...
...in Japan and South Korea for bronchial asthma, keloid and hypertrophic scars and allergic conjunctivitis. Nuon's...
...the program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jul 20, 2009
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Neurology Hired: Paulette Dillon as CBO, formerly CBO at Anacor Pharmaceuticals Inc. ; and Tito Serafini as CSO, formerly VP at Renovis Inc. (now part of Evotec...
BioCentury | Jul 20, 2009
Company News

Nuon board of directors update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Neurology Elected: Arlene Morris, president and CEO of Affymax Inc. , as chairperson WIR Staff autoimmune Neurology...
Items per page:
1 - 10 of 16
BioCentury | Aug 15, 2011
Company News

Tobira management update

...Manalapan, N.J. Business: Infectious Hired: Helen Jenkins as SVP of program leadership, formerly COO at Nuon Therapeutics Inc. WIR...
BioCentury | Jul 25, 2011
Company News

Portola management update

...Cardiovascular, Autoimmune, Cancer Hired: Michael Kitt as SVP and CMO, formerly EVP and CMO of Nuon Therapeutics Inc. WIR...
BioCentury | Jul 19, 2010
Clinical News

Tranilast: Phase I data

...total daily doses of 300, 600 or 900 mg tranilast between once- or twice-daily regimens. Nuon...
...keloid and hypertrophic scars and allergic conjunctivitis. Kissei was granted an exclusive option to license Nuon's...
...tranilast program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jul 19, 2010
Clinical News

Tranilast: Phase I data

...asthma, keloid and hypertrophic scars and allergic conjunctivitis. Kissei has an exclusive option to license Nuon's...
...tranilast program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jun 21, 2010
Clinical News

NU1618: Phase IIa data

...Patients received low- or high-dose NU1618, 300 mg/day tranilast, or 300 or 400 mg/day allopurinol. Nuon...
...in Japan and South Korea for bronchial asthma, keloid and hypertrophic scars and allergic conjunctivitis. Nuon's...
...the program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | May 17, 2010
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Metabolic Hired: Lee Rauch as president and CEO, formerly acting head of corporate development of Onyx Pharmaceuticals Inc. WIR Staff...
BioCentury | May 13, 2010
Company News

Nuon names Rauch CEO

...Autoimmune and metabolic company Nuon Therapeutics Inc. (San Mateo, Calif.) hired Lee Rauch as president and CEO. She...
BioCentury | Apr 26, 2010
Clinical News

NU1618: Phase IIb start

...This month, Nuon will begin a double-blind, active-controlled Phase IIb trial in 60 patients to compare...
...in Japan and South Korea for bronchial asthma, keloid and hypertrophic scars and allergic conjunctivitis. Nuon's...
...the program for autoimmune indications in Japan and South Korea (see BioCentury, July 30, 2007). Nuon Therapeutics Inc....
BioCentury | Jul 20, 2009
Company News

Nuon management update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Neurology Hired: Paulette Dillon as CBO, formerly CBO at Anacor Pharmaceuticals Inc. ; and Tito Serafini as CSO, formerly VP at Renovis Inc. (now part of Evotec...
BioCentury | Jul 20, 2009
Company News

Nuon board of directors update

Nuon Therapeutics Inc. , San Mateo, Calif. Business: Autoimmune, Neurology Elected: Arlene Morris, president and CEO of Affymax Inc. , as chairperson WIR Staff autoimmune Neurology...
Items per page:
1 - 10 of 16